| | Principal Investigators
| Philip W. Gold, M.D. |
 |
|
Dr.
Gold received his BA and MD degrees from Duke University.
He received his training in psychiatry at Harvard University
and his training in endocrinology at the NIH. He is
currently Chief of the Clinical
Neuroendocrine Branch, a program that focuses
on the premature coronary artery disease and osteoporosis
associated with major depression, indepedent of traditional
risk factors. He is serving as a Member of the Library
of Congress Council of Scholars. |
| Research Interests |
| Dr.
Gold's group focuses on the neural circuitry and mediators
of the response to stressful stimuli and their potential
to become dysregulated in major depression.
His group is working on an interrelated cascade of autonomic,
endocrine, metabolic, inflammatory, and hemostatic mediators
that is abnormal in patients with major depression and
may contribute to premature coronary artery disease
and osteoporosis in major depression. In premenopausal
women with major depression he has found that major depression
is an independent risk factor for osteopenia or osteoporosis.
Dr. Gold has recently spearheaded studies with the corticotrophin releasing
hormone receptor antagonist antalarmin, which he and
his colleagues have found plays a comprehensive role
in the behavioral and physiological responses to stress
in non-human primates. |
| Representative Selected Recent Publications: |
- Gold PW, Wong ML, Goldstein DS, Gold HK, Ronsaville DS, Esler M, Alesci S, Masood A, Licinio J, Geracioti TD, Perini G, DeBellis MD, Holmes C, Vgontzas AN, Charney DS, Chrousos GP, McCann SM, Kling MA:
Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia.
Proceedings of the National Academy of Sciences USA, 102: 8303-8308, 2005. (View PDF)
- Wong ML, O�Kirwwan F, Khan N, Hannestad J, Wu KH, Elashoff D, Lawson G, Gold PW, McCann SM, Licinio J:
Identification, characterization, and gene expression profiling of endotoxin-induced myocarditis
Proceedings of the National Academy of Sciences USA<, 100: 14241-14246, 2003. (View PDF)
- Contoreggi C, Herning RI, Na P, Gold PW, Chrousos G, Negro PJ, Better W, Cadet JL:
Stress hormone responses to corticotropin-releasing hormone in substance abusers without severe comorbid psychiatric disease.
Biological Psychiatry, 54: 873-878, 2003. (View PDF)
- Gold PW, Drevets WC, Charney DS:
New insights into the role of cortisol and the glucocorticoid receptor in severe depression.
Biological Psychiatry, 52: 381-5, 2002. (View PDF)
- Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD, Gold PW:
Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.
Proceedings of the National Academy of Sciences USA, 97: 6079-6084, 2000. (View PDF)
- Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, Karp B, McCutcheon IE, Geracioti TD Jr, DeBellis MD, Rice KC, Goldstein DS, Veldhuis JD, Chrousos GP, Oldfield EH, McCann SM, Gold PW:
Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone.
Proceedings of the National Academy of Sciences USA, 97: 325-330, 2000. (View PDF)
|
|
|
|
|
